Citius Pharmaceuticals, Inc.

What they do

Citius Pharmaceuticals develops and commercializes first-in-class critical care products. Its lead commercial asset is LYMPHIR (denileukin diftitox), an oncology immunotherapy licensed from Eisai for the treatment of cutaneous T-cell lymphoma (CTCL), a rare non-Hodgkin lymphoma. LYMPHIR sales began in December 2025 and are run through majority-owned Citius Oncology, Inc. (Nasdaq: CTOR), which was formed in 2024. The company also holds Mino-Lok, an antibiotic solution for catheter-related bloodstream infections, and a 75% stake in NoveCite, a stem cell therapy joint venture.

Revenue drivers

• LYMPHIR commercial sales — The only revenue-generating product. Sales commenced in December 2025 and generated $7.1 million in the first nine months of fiscal 2026, with quarterly revenue of $3.9M in the December 2025 quarter, $1.7M in March 2026, and $1.5M in June 2026.
• Mino-Lok — Not yet commercialized. The company acquired the asset in 2016 and has recorded $19.4 million of in-process research and development; no product revenue has been reported.
• NoveCite stem cell therapy — A 75%-owned subsidiary formed in 2020 under a license from Novellus Therapeutics. No revenue has been reported from this program.
• Legacy license and maintenance fees — Immaterial historical revenue of $90,000 per year from 2019 through 2022. Not a current driver of the business.

Recent performance

For the fiscal third quarter ended June 30, 2026, Citius reported revenue of $1.5 million, down from $3.9 million in the December 2025 quarter and $1.7 million in the March 2026 quarter, according to the 8-K earnings release dated August 14, 2026. First-nine-month fiscal 2026 LYMPHIR revenue was $7.1 million. Cash and cash equivalents stood at $17.0 million as of June 30, 2026, against total liabilities of $66.3 million and shareholder equity of $66.6 million. The company reported an 80% increase in new institutions ordering LYMPHIR and a 31% increase in institutional vial orders from wholesalers during the quarter. Annual net losses have been substantial, at $39.4 million in fiscal 2024 and $39.7 million in fiscal 2025, with operating cash flow of negative $26.6 million in fiscal 2025.

Strategy

Management's stated priority is scaling the LYMPHIR launch, which it describes as the primary driver of the business. The company completed nationwide deployment of an expanded Citius Oncology commercial and medical affairs team totaling 29 professionals in August 2026, working through EVERSANA, its exclusive commercialization partner. It is also pursuing label expansion through investigator-initiated Phase 1 trials, including LYMPHIR with pembrolizumab in gynecologic malignancies and LYMPHIR prior to CAR-T therapy in DLBCL. The company raised approximately $4.5 million in net proceeds from an April 2026 registered direct offering and approximately $9.7 million from warrant exercises, and funded $10.0 million under the first tranche of a Citius Oncology senior secured term loan facility. Management states it remains focused on disciplined execution and long-term value of LYMPHIR.

Risks

• Listing-rule failure — The company disclosed a delisting notice or listing-rule failure in an 8-K filed August 21, 2026, which could affect the liquidity and marketability of CTXR common stock.
• Early-stage commercial execution — LYMPHIR revenue declined sequentially across fiscal 2026 quarters, from $3.9 million to $1.7 million to $1.5 million, indicating uncertain demand ramp.
• Cash burn and financing need — The company had $17.0 million in cash at June 30, 2026 against $66.3 million in total liabilities and negative operating cash flow of $26.6 million in fiscal 2025, requiring continued capital raises.
• Subsidiary dependence and governance — LYMPHIR revenue is generated through majority-owned Citius Oncology (CTOR), in which CEO Leonard Mazur also serves as President and CEO, concentrating operational and related-party exposure.

Outlook

Management expects the expanded 29-person commercial and medical affairs organization to increase engagement with priority treatment centers, support formulary adoption and broaden patient access as the LYMPHIR launch matures. The company reported near-universal payer coverage with no reimbursement denials or preauthorization barriers reported to date. It also points to Phase 1 investigator-initiated data in gynecologic malignancies and DLBCL as evidence of LYMPHIR's potential beyond cutaneous T-cell lymphoma. No specific revenue or earnings guidance was provided.